



8th ANNUAL GENERAL MEETING

HYPHENS PHARMA INTERNATIONAL LIMITED

Prepared by
Lim See Wah

Date
28/04/2026



DISCLAIMER

This presentation has been prepared by Hyphens Pharma International Limited (the "Company") and, together with its subsidiaries, the "Group").

This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated, photographed or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated or quoted, directly or indirectly, to any person either in your organisation or elsewhere. None of the Company, SAC Capital Private Limited (the "Sponsor") nor any of their respective affiliates, advisors and representatives makes any representation regarding, or assumes any responsibility or liability whatsoever (in negligence or otherwise) for, the accuracy or completeness of, or any errors or omissions in, any information contained herein nor for any loss howsoever arising from any use of the content in this presentation.

By attending or viewing all or part of this presentation, you:

1. represent and warrant that you are lawfully able to receive this presentation under the laws of the jurisdiction in which you are located and all other applicable laws;

2. agree to be bound by the limitations and restrictions described herein; and

3. agree to maintain confidentiality regarding the information disclosed in this presentation and to continue to adhere to all applicable securities and insider trading rules and laws in any jurisdiction at all times.

This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in Singapore or any other jurisdiction nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

The information in this presentation is a summary only and does not purport to contain all of the information that may be required to evaluate the Company or any potential transaction. Any potential transaction could be made available to you in accordance with applicable laws and regulations, including the distribution of any required documents for such potential transaction and such documents will supersede all prior information provided to you, herein or otherwise. Information in this presentation is qualified in its entirety by reference to an offering document for any potential transaction, if it proceeds.

None of the Company, the Sponsor, and any of their respective holding companies, subsidiaries, associated undertakings, controlling persons, affiliates, and any of their respective directors, officers, partners, employees, agents, advisers or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation. It is not the intention to provide, and you may not rely on the content of this presentation as providing, a complete or comprehensive analysis of the Company's or the Group's financial or trading position or prospects. The information and opinions contained in this presentation is provided as at the date hereof (unless otherwise indicated) and are subject to change without notice. This presentation may not contain all material information concerning the Company or the Group.

The information contained in this presentation has not been independently verified. The accuracy and completeness of the information and opinions in this presentation is not guaranteed and no representation or warranty, expressed or implied, is made as to, and no reliance, in whole or in part, should be placed on the fairness, accuracy, completeness or correctness of the information, opinions or assumptions contained herein. Further, nothing in this presentation should be construed as constituting legal, business, tax or financial advice. None of the Sponsor and its subsidiaries or affiliates has independently verified, approved or endorsed the material herein.

The information in this presentation includes historical information about and relevant to the Group that should not be regarded as an indication of the future performance of the Group or the value of the shares of the Company. This presentation also contains forward-looking statements that may be identified by their use of words like "plans", "expects", "will", "anticipates", "believes", "intends", "depends", "projects", "estimates" or other words of similar meaning and that involve assumptions, risks and uncertainties. All statements that address expectations or projections about the future and all statements other than statements of historical facts included in this presentation, including, but not limited to, statements about the strategy for growth, product development, market position, expenditures, and financial results, are forward-looking statements. Such forward-looking statements are based on certain assumptions and expectations of future events regarding the Group's present and future business strategies and the environment in which the Group will operate, and must be read together with those assumptions. No assurance or guarantee is given that these assumptions and expectations are accurate or will be realised. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. These risks, uncertainties and assumptions include, without limitation, general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other entities, shifts in customer demand, customers and partners, changes in operating expenses including employee wages, benefits and training, governmental and public policy changes and the continued availability of financing in the amounts and the terms necessary to support future business. Predictions, projections or forecasts of the economy or economic trends of the markets are not necessarily indicative of the future or likely performance of the Group. Past performance is not necessarily indicative of future performance. You are cautioned not to place undue reliance on these forward-looking statements, which are based on the Company's current view of future events. None of the Company and the Sponsor, their respective affiliates and their respective agents assumes any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise.

Neither this presentation nor any of its content may be used without the prior written consent of the Company and the Sponsor. Any forwarding, distribution or reproduction of the information in this presentation electronically or otherwise, in whole or in part, is unauthorised.

AGENDA

1. **FY2025 Financial Updates**
2. **Business Updates**
3. **Commitment to Sustainability**
4. **Unlock Shareholders' Value**
5. **Business Outlook**




01

FY2025 Financial Updates




Group Financial Results- Revenue

REVENUE (\$\$'MIL)




GROSS PROFIT (\$\$'MIL) & GROSS PROFIT MARGIN (%)




In 2H2025, the GPM has achieved **42%**. Both gross profit and GPM has achieved historical high in FY2025.

Group Financial Results - Profits

PROFITS, NET OF TAX (S\$'MIL)



NORMALISED PROFIT BEFORE TAX FOR 2H2025 (S\$'MIL)




Normalisation items:


Non-operating items include fair value gain from derivative instrument in relation to Ardence Pharma Acquisition of S\$0.17m in 2H2023, S\$0.18m in 2H2024, and fair value loss of S\$0.25m in 2H2025 due to exercise of Ardence Pharma Tranche 2 acquisition;

Non-recurring item includes provision for loan to VietPOM business of S\$0.59m in 2H2025


Group Financial Results - Cashflow



REVENUE BY BUSINESS SEGMENT



REVENUE BY GEOGRAPHY



REWARDING OUR SHAREHOLDERS

18.5%

increase in
Volume
Weighted
Average Price
(VWAP) from
2024 to 2025

SGD1.5

cent/share
dividend
proposed



02

BUSINESS UPDATES



WE HAVE 3 REVENUE SEGMENTS

01

Specialty
Pharmaceutical
Principals




02

Proprietary
Brands



03

Medical Hypermart
& Digital



UPDATING THE NAMES OF OUR SEGMENTS

01

Pharmaceutical &
Medical Aesthetics




02

Proprietary
Brands



03

Digital Platform & E-
Pharmacy



PHARMACEUTICAL & MEDICAL AESTHETICS



- Improved **product mix** drove **margin improvements**;
- Our Specialty pharmaceuticals remained a **core part** of this segment & **growing steadily**.
- Medical Aesthetic business is growing and making **impactful contribution** to this segment.
- The Group has enhanced its inventory management to **reduce obsolescence risk**, while remaining mindful of external uncertainties such as geopolitical tensions, which may impact supply chains, inflation, and foreign exchange.

PROPRIETARY BRANDS

- Winlevi® was launched in Singapore and Malaysia during July 2025.
- Ceradan®
 - Launched Ceradan® Daily Moisturising Cream with prebiotics in Southeast Asia in February 2025, starting with Singapore and Malaysia.
- CeraPro® MED
 - Distinct from Ceradan, as it is approved in Europe for treatment of atopic dermatitis
 - First out-licensing deal for 6 European countries. Launch expected in 2026.
- Ocean Health®
 - Launched Multivitamin & Minerals Refill Pack during September 2025, a comprehensive once daily formula of essential nutrients, packaged with 85% less plastic.
- Reclassification of VisioPro® and Fenosup®, reflecting products for which we hold intellectual property rights in full or by geography;



DIGITAL PLATFORM & E-PHARMACY



- Wellaway e-pharmacy continued to show strong growth momentum in FY2025;
- Introduced POM 5.0 to healthcare professionals in Singapore and Malaysia, with clinic outreach activities during 2H 2025.

03

COMMITMENT TO SUSTAINABILITY





FY2025 SUSTAINABILITY REPORT



Hyphens Pharma
International Limited

CONTENTS

03 About This Report	18 TCFD Report
04 Governance	28 Our Customers
07 Our Sustainability Strategy	31 Our Supply Chain
08 Stakeholders	32 Our Communities
09 Materiality	36 GRI Content Index
10 Our People	40 TCFD Content Index
16 Our Environment	

This Sustainability Report has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "Sponsor"). This Sustainability Report has not been examined or approved by Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this Sustainability Report, including the correctness of any of the statements or opinions made or reports contained in this Sustainability Report.

The contact person for the Sponsor is Ms Lee Khal Yin, Tel: (65) 6232 3210 at 1 Robinson Road, #21-01 AIA Tower, Singapore 048542.

As part of our ESG commitment, the Group published its FY2025 Sustainability Report only in electronic format this year.

(<https://links.sgx.com/FileOpen/Hyphens%20Pharma%20SR%202025.ashx?App=Announcement&FileID=884570>)

DELIVERING SUSTAINABLE GROWTH AND GOVERNANCE



Packaging waste



To increase the number of units of refill packs by 1.5x the 2024 baseline by

2030



Green House Gas (“GHG”) emission

Reduced to

406.9

tonnes of CO₂e in FY2025 from 470.2 tCO₂e in FY2024

Our subsidiary, Pan-Malayan, is advancing its climate strategy through the **transition** of its fleet to **electric vehicles**.



Talent Management

474 **66%** **59%**

full time employee are female Senior management positions are female

3,786

hours of training

92

New hires

04


Unlock Shareholders' Value



IMPROVED SHARE PRICE AND TRADING VOLUME

S\$0.281  S\$0.333
VWAP 2024 VWAP 2025 ▲ 18.5%

Monthly Trading Volume (k)



Driving Market Re-Rating

External factors

Supportive External Environment – EQDP

- EQDP inclusion enhanced visibility and institutional reach
- Improved liquidity and trading velocity
- Stronger price discovery supported valuation uplift

Internal efforts

Analyst Briefing (Aug 2025)

- Transparent explanation of earnings dip & FX impact
- Clarified Group Strategy and growth roadmap
- First detailed articulation of Hyphens' business model
- Reduced uncertainty discount and strengthened investor confidence

WHAT WILL WE DO?

1

Financial Performance

- ROA
- ROE
- Cash flow



2

Branding and Communication



3

Investor Engagement



05

BUSINESS OUTLOOK



STRATEGIC PRIORITIES & GROWTH DRIVER

1. Growing our Proprietary Brands:

- ❑ Winlevi®, the first-in-class topical new drug for acne, has just been launched in Singapore & Malaysia. Other major ASEAN countries are in registration process

- ❑ Strengthened by high-strength “Live Probiotics” under our own trademark VisioPro® *

** Previously marketed as Vivomixx®, which was not our trademark.*


- ❑ Continue to drive growth of Ceradan® & Ocean Health®.



STRATEGIC PRIORITIES & GROWTH DRIVER

2. Strengthening our Pharmaceutical & Medical Aesthetic segment:

- ❑ Diligently and consistently growing our core specialty pharmaceutical brands.
 - ❑ *Deliver sustainable profitable growth*
- ❑ Making Medical Aesthetics another engine of growth.
 - ❑ Beyond Singapore & Malaysia, we have already started in Philippines, Indonesia and Thailand.



3. Acquisition:

- ❑ Completed Tranche 2 acquisition of Ardence Pharma in 1H 25, bringing our total shareholding to 82%. The last tranche is expected to take place in 1H 26.
- ❑ Continue to source for acquisition opportunities.



06

Questions & Answers



07

Resolutions



RESOLUTION 1

To receive and adopt the Directors' Statement and the Audited Financial Statements of the Company for the financial year ended 31 December 2025 together with the Auditors' Report.

RESOLUTION 2

To declare a final tax exempt (one-tier) dividend of 1.50 Singapore cents per ordinary share for the financial year ended 31 December 2025.

RESOLUTION 3

To re-elect Dr Tan Kia King who is retiring pursuant to Regulation 97 of the Company's Constitution, as a Director of the Company.

RESOLUTION 4

To re-elect Mr Chan Kiat who is retiring pursuant to Regulation 97 of the Company's Constitution, as a Director of the Company.

RESOLUTION 5

To approve the payment of Directors' fees of S\$282,000 for the financial year ended 31 December 2025.

RESOLUTION 6

To re-appoint RSM SG Assurance LLP as the Auditors of the Company and to authorise the Directors to fix their remuneration.

RESOLUTION 7

To authorise the Directors to allot and issue new shares and/or convertible securities pursuant to Section 161 of the Companies Act 1967 and Rule 806 of the SGX-ST Listing Manual Section B: Rules of Catalist.

RESOLUTION 8

To authorise the Directors to grant awards and to allot and issue shares in accordance with Hyphens Performance Share Plan.

RESOLUTION 9

To authorise the Directors to grant options and to allot and issue shares in accordance with Hyphens Employee Share Option Scheme.

RESOLUTION 10

To approve the proposed renewal of the share buy-back mandate.

TIME FOR A BREAK



POLL RESULTS



POLL RESULTS

Resolutions	Votes in Favour		Votes Against	
	No. of Shares	%	No. of Shares	%
1. To receive and adopt the Directors' Statement and the Audited Financial Statements of the Company for the financial year ended 31 December 2025 together with the Auditors' Report.	240,558,300	99.97	65,000	0.03
2. To declare a final tax exempt (one-tier) dividend of 1.50 Singapore cents per ordinary share for the financial year ended 31 December 2025.	240,558,300	99.97	65,000	0.03
3. To re-elect Dr Tan Kia King who is retiring pursuant to Regulation 97 of the Company's Constitution, as a Director of the Company.	164,253,941	99.96	65,000	0.04
4. To re-elect Mr Chan Kiat who is retiring pursuant to Regulation 97 of the Company's Constitution, as a Director of the Company.	240,388,100	99.97	65,000	0.03

POLL RESULTS

Resolutions	Votes in Favour		Votes Against	
	No. of Shares	%	No. of Shares	%
5. To approve the payment of Directors' fees of S\$282,000 for the financial year ended 31 December 2025.	240,388,100	99.97	65,000	0.03
6. To re-appoint RSM SG Assurance LLP as the Auditors of the Company and to authorise the Directors to fix their remuneration.	240,558,300	99.97	65,000	0.03
7. To authorise the Directors to allot and issue new shares and/or convertible securities pursuant to Section 161 of the Companies Act 1967 and Rule 806 of the SGX-ST Listing Manual Section B: Rules of Catalist.	235,486,300	97.87	5,137,000	2.13

POLL RESULTS

Resolutions	Votes in Favour		Votes Against	
	No. of Shares	%	No. of Shares	%
8. To authorise the Directors to grant awards and to allot and issue shares in accordance with Hyphens Performance Share Plan.	234,673,900	97.86	5,137,000	2.14
9. To authorise the Directors to grant options and to allot and issue shares in accordance with Hyphens Employee Share Option Scheme.	234,673,900	97.86	5,137,000	2.14
10. To approve the proposed renewal of the share buy-back mandate.	240,558,300	99.97	65,000	0.03

THANK YOU Let's improve lives together.

Hyphens Pharma International Limited (SGX: 135)

16 Tai Seng Street, Level 4, Singapore 534138

 hyphens-pharma-international

 <https://www.hyphensgroup.com/>

